公开(公告)号：US09789078B2

公开(公告)日：2017-10-17

申请号：US14401492

申请日：2013-05-15

Applicant: LEO Laboratories Limited

Inventor： Kirsten Norrelund

IPC: A61K31/22 ,  A61K31/215 ,  A61K9/00

CPC classification number: A61K31/22 ,  A61K9/0014 ,  A61K31/215

Abstract: The present invention relates to cyclic or repeated use of the ingenol mebutate for topical treatment of actinic keratosis lesions. Generally speaking, the present invention comprises a first ingenol mebutate treatment cycle and a second ingenol mebutate treatment cycle, wherein the first treatment cycle topically treats a treatment area with a topical gel formulated with ingenol mebutate at a selected dosage strength for a specified treatment regimen, and the second ingenol mebutate treatment cycle comprises topically re-treating the treatment area with the same topical ingenol mebutate gel for the same specified treatment regimen, if following the first treatment cycle, the treatment area failed to clear or failed to remain clear of AK lesions. The present invention further relates to spot or individual lesion therapy in the treatment area following the topical bi-cyclic therapy with ingenol mebutate.

公开(公告)号：US20150133542A1

公开(公告)日：2015-05-14

申请号：US14401492

申请日：2013-05-15

Applicant: LEO Laboratories Limited

Inventor： Kirsten Norrelund

IPC: A61K31/22 ,  A61K9/00

CPC classification number: A61K31/22 ,  A61K9/0014 ,  A61K31/215

Abstract: The present invention relates to cyclic or repeated use of the ingenol mebutate for topical treatment of actinic keratosis lesions. Generally speaking, the present invention comprises a first ingenol mebutate treatment cycle and a second ingenol mebutate treatment cycle, wherein the first treatment cycle topically treats a treatment area with a topical gel formulated with ingenol mebutate at a selected dosage strength for a specified treatment regimen, and the second ingenol mebutate treatment cycle comprises topically re-treating the treatment area with the same topical ingenol mebutate gel for the same specified treatment regimen, if following the first treatment cycle, the treatment area failed to clear or failed to remain clear of AK lesions. The present invention further relates to spot or individual lesion therapy in the treatment area following the topical bi-cyclic therapy with ingenol mebutate.

Abstract translation: 本发明涉及用于局部治疗光化性角化病病变的内酯醇甲醇的循环或重复使用。 一般而言，本发明包括第一种异烯醇醇甲醇酸酯处理循环和第二种异烯醇醇甲醇处理循环，其中第一处理循环以特定的处理方案以选定的剂量强度局部用局部用凝胶配制的局部凝胶治疗处理区域， 并且第二内酯醇治疗周期包括用相同的特定治疗方案用相同的局部西梅替丁凝胶局部再治疗治疗区域，如果在第一个治疗周期之后，治疗区域未能清除或不能保持清除AK病变 。 本发明还涉及局部用环内酯类药物治疗双侧治疗后的治疗区域中的斑点或个体病变治疗。